Hoitsma A J, Reekers P, van Lier H J, van Rens J C, Koene R A
Transplantation. 1984 Jul;38(1):25-8. doi: 10.1097/00007890-198407000-00006.
The influence of DRw6-antigen on graft survival was studied in a single-center study in 223 recipients of a cadaveric kidney. Although graft survival in 148 DRw6-negative recipients was not significantly different from that in 75 DRw6-positive recipients, the percentage of patients without a rejection episode in the first three months after grafting was significantly less in the DRw6-negative recipients (p = 0.03). In DRw6-positive patients who had received rabbit antithymocyte globulin (RATG) as the first antirejection treatment, graft survival was significantly better than in prednisone-treated DRw6-positive recipients. In the DRw6-negative patients RATG treatment also gave better results, but these differences were not significant. When RATG-treated patients were excluded from the analysis, the difference in graft survival between DRw6-negative and DRw6-positive patients became apparent (p = 0.03). These findings show that the negative influence of the DRw6 antigen present in the recipients is counterbalanced by the beneficial effect of RATG treatment for first rejection episodes.
在一项针对223名尸体肾移植受者的单中心研究中，研究了DRw6抗原对移植物存活的影响。虽然148名DRw6阴性受者的移植物存活情况与75名DRw6阳性受者并无显著差异，但DRw6阴性受者在移植后前三个月无排斥反应发作的患者百分比显著更低（p = 0.03）。在接受兔抗胸腺细胞球蛋白（RATG）作为首次抗排斥治疗的DRw6阳性患者中，移植物存活情况显著优于接受泼尼松治疗的DRw6阳性受者。在DRw6阴性患者中，RATG治疗也取得了更好的结果，但这些差异并不显著。当将接受RATG治疗的患者排除在分析之外时，DRw6阴性和DRw6阳性患者之间的移植物存活差异变得明显（p = 0.03）。这些发现表明，受者体内存在的DRw6抗原的负面影响被RATG治疗对首次排斥反应发作的有益作用所抵消。
